JP2021525783A5 - - Google Patents

Info

Publication number
JP2021525783A5
JP2021525783A5 JP2020568258A JP2020568258A JP2021525783A5 JP 2021525783 A5 JP2021525783 A5 JP 2021525783A5 JP 2020568258 A JP2020568258 A JP 2020568258A JP 2020568258 A JP2020568258 A JP 2020568258A JP 2021525783 A5 JP2021525783 A5 JP 2021525783A5
Authority
JP
Japan
Prior art keywords
hydroxymethyl
benzyl
pyridine
pyrazine
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020568258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525783A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/090221 external-priority patent/WO2019233457A1/zh
Publication of JP2021525783A publication Critical patent/JP2021525783A/ja
Publication of JP2021525783A5 publication Critical patent/JP2021525783A5/ja
Pending legal-status Critical Current

Links

JP2020568258A 2018-06-08 2019-06-06 Erk阻害剤及びその使用 Pending JP2021525783A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/090385 2018-06-08
CN2018090385 2018-06-08
CN2018120975 2018-12-13
CNPCT/CN2018/120975 2018-12-13
PCT/CN2019/090221 WO2019233457A1 (zh) 2018-06-08 2019-06-06 Erk抑制剂及其应用

Publications (2)

Publication Number Publication Date
JP2021525783A JP2021525783A (ja) 2021-09-27
JP2021525783A5 true JP2021525783A5 (enExample) 2022-05-16

Family

ID=68770778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568258A Pending JP2021525783A (ja) 2018-06-08 2019-06-06 Erk阻害剤及びその使用

Country Status (11)

Country Link
US (1) US11466013B2 (enExample)
EP (1) EP3805217A4 (enExample)
JP (1) JP2021525783A (enExample)
KR (1) KR20210018915A (enExample)
CN (1) CN112204024B (enExample)
AU (1) AU2019280356B2 (enExample)
CA (1) CA3103055A1 (enExample)
IL (1) IL279276A (enExample)
SG (1) SG11202012241RA (enExample)
TW (1) TW202016102A (enExample)
WO (1) WO2019233457A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4071155A4 (en) * 2019-12-06 2024-01-17 D3 Bio (Wuxi) Co., Ltd. Thiazololactam compound as erk inhibitor and use thereof
WO2022253186A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 一种二甲基取代的噻唑并吡咯酮类化合物的晶型及其制备方法
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors
EP4366733A4 (en) * 2021-08-11 2025-06-25 Landos Biopharma, Inc. TETRAHYDROPYRAZOLOPYRIDINE ANALOGUES OF NLRX1 LIGANDS AND THEIR USES
WO2024218632A1 (en) * 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
CN117209485A (zh) * 2023-08-31 2023-12-12 四川大学华西医院 一种具有抗肿瘤活性的嘧啶骨架类化合物及其制备方法和应用
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4783532B2 (ja) * 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
GB0614070D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
CN101796036A (zh) * 2007-08-02 2010-08-04 欧加农股份有限公司 作为trpv1调节剂的5-苯基异噁唑-3-甲酰胺衍生物
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
CN107922387B (zh) * 2015-06-15 2024-11-22 阿沙纳生物科学公司 Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用
WO2017080980A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer

Similar Documents

Publication Publication Date Title
CN112204027A (zh) Erk 抑制剂及其应用
JP2024532735A (ja) 複素環式化合物及び使用方法
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
WO2021149817A1 (en) Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
JP2024532733A (ja) 複素環式化合物及び使用方法
EP4479401A1 (en) Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP2025533831A (ja) Kras g12c変異タンパク質のテザー型複素環式阻害剤及びその使用
JP2013534902A5 (enExample)
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
JP2022552324A5 (enExample)
RU2017112518A (ru) Пиридоновые и азапиридоновые соединения и способы применения
JP2011516558A5 (enExample)
JP2016537384A5 (enExample)
JP2019535664A5 (enExample)
WO2022093856A1 (en) Heterocyclic spiro compounds and methods of use
JP2023549055A5 (enExample)
JP2011500774A5 (enExample)
JP2015511245A5 (enExample)
JP2021521165A5 (enExample)
JP2017503867A5 (enExample)
JPWO2022173033A5 (enExample)
RU2017141077A (ru) Ингибитор некоторых протеинкиназ